Ascendis Pharma Seeks FDA Expansion for TransCon hGH

Ascendis Pharma (ASND) has released an update.

Ascendis Pharma A/S has announced the submission of a supplemental Biologics License Application to the FDA for TransCon hGH, aiming to expand its use to adult growth hormone deficiency treatment. The application is bolstered by positive results from the foresiGHt Phase 3 trial, which demonstrated the drug’s effectiveness and safety compared to both placebo and daily hGH treatments in adults. The trial’s outcome, showing significant improvements in body composition, positions TransCon hGH as a promising weekly alternative therapy for adults with growth hormone deficiency.

For further insights into ASND stock, check out TipRanks’ Stock Analysis page.